CY1107616T1 - Καινοτομος χρηση της 2-[5-(4-φθοροφαινυλο)-3-πυριδυλομεθυλαμινομεθυλο]-χρωμανης και των φυσιολογικα αποδεκτων αλατων της - Google Patents

Καινοτομος χρηση της 2-[5-(4-φθοροφαινυλο)-3-πυριδυλομεθυλαμινομεθυλο]-χρωμανης και των φυσιολογικα αποδεκτων αλατων της

Info

Publication number
CY1107616T1
CY1107616T1 CY20071100526T CY071100526T CY1107616T1 CY 1107616 T1 CY1107616 T1 CY 1107616T1 CY 20071100526 T CY20071100526 T CY 20071100526T CY 071100526 T CY071100526 T CY 071100526T CY 1107616 T1 CY1107616 T1 CY 1107616T1
Authority
CY
Cyprus
Prior art keywords
pyridylmethylaminomethyl
fluorophenyl
physiologically acceptable
chroman
acceptable salts
Prior art date
Application number
CY20071100526T
Other languages
English (en)
Inventor
Gerd Bartoszyk
Hermann Russ
Christoph Seyfried
Frank Weber
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of CY1107616T1 publication Critical patent/CY1107616T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η (R/S)-(-/+)-2-[5-(4-φθoρoφαινυλo)-3-πυριδυλομεθυλαμινομεθυλο] χρωμάνη ή ένα φυσιολογικά αποδεκτό άλας της, και/ή η (S)-(+)-2-[5-(4-φθοροφαινυλο)-3-πυριδυλομεθυλαμινομεθυλο] χρωμάνη ή ένα φυσιολογικά αποδεκτό άλας της χρησιμοποιούνται για την παρασκευή ενός φαρμάκου για τη θεραπεία εξωπυραμιδικών διαταραχών της κίνησης και/ή δυσμενών επιδράσεων στις εξωπυραμιδικές διαταραχές της κίνησης.
CY20071100526T 2001-07-26 2007-04-19 Καινοτομος χρηση της 2-[5-(4-φθοροφαινυλο)-3-πυριδυλομεθυλαμινομεθυλο]-χρωμανης και των φυσιολογικα αποδεκτων αλατων της CY1107616T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01118097 2001-07-26
EP02790172A EP1408964B1 (en) 2001-07-26 2002-07-10 Use of 2- 5-(4-fluorophenyl)-3-pyridylmethylaminomethyl|-chromane and its physiologically acceptable salts

Publications (1)

Publication Number Publication Date
CY1107616T1 true CY1107616T1 (el) 2013-03-13

Family

ID=8178137

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100526T CY1107616T1 (el) 2001-07-26 2007-04-19 Καινοτομος χρηση της 2-[5-(4-φθοροφαινυλο)-3-πυριδυλομεθυλαμινομεθυλο]-χρωμανης και των φυσιολογικα αποδεκτων αλατων της

Country Status (24)

Country Link
US (1) US7872030B2 (el)
EP (1) EP1408964B1 (el)
JP (1) JP2004538289A (el)
KR (1) KR20040029325A (el)
CN (1) CN1292749C (el)
AR (1) AR037496A1 (el)
AT (1) ATE352302T1 (el)
AU (1) AU2002355170B2 (el)
BR (1) BR0211358A (el)
CA (1) CA2455621C (el)
CY (1) CY1107616T1 (el)
DE (1) DE60217870T2 (el)
DK (1) DK1408964T3 (el)
ES (1) ES2280602T3 (el)
HK (1) HK1068793A1 (el)
HU (1) HUP0402092A3 (el)
MX (1) MXPA04000775A (el)
MY (1) MY134059A (el)
PE (1) PE20030277A1 (el)
PL (1) PL208258B1 (el)
PT (1) PT1408964E (el)
RU (1) RU2297833C2 (el)
SI (1) SI1408964T1 (el)
WO (1) WO2003009835A2 (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5517453B2 (ja) 2005-07-26 2014-06-11 ノヴィファーマ，エス．アー． Ｃｏｍｔ阻害剤
EP1845097A1 (en) * 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
CA2678391C (en) 2007-01-31 2017-01-17 David Alexander Learmonth Dosage regimen for comt inhibitors
RU2010139315A (ru) 2008-03-17 2012-04-27 Биал - Портела Энд Ка., С.А. (Pt) Кристаллические формы 5-[3-(2,5-дихлор-4,6-диметил-1-окси-пиридин-3-ил)[1,2,4]оксадиазол-5-ил]-3-нитробензол-1,2-диола
CN102448444B (zh) 2009-04-01 2016-05-25 巴尔-波特拉及康邦亚股份有限公司 包括硝基儿茶酚衍生物的药物制剂及其制备方法
JP5809146B2 (ja) 2009-09-11 2015-11-10 アイシス ファーマシューティカルズ， インコーポレーテッド ハンチンチン発現の修飾
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
EP3604299B1 (en) 2011-12-13 2023-07-26 Bial-Portela & CA, S.A. Chemical compound useful as intermediate for preparing a catechol-0-methyl transferase inhibitor
WO2016083863A1 (en) 2014-11-28 2016-06-02 Bial - Portela & Ca, S.A. Medicaments for slowing parkinson's disease

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US576132A (en) * 1897-02-02 Current water-wheel
DE2364685C3 (de) 1973-12-27 1978-06-15 Beiersdorf Ag, 2000 Hamburg Phenoxyäthylamine
US4438119A (en) * 1982-12-23 1984-03-20 Mead Johnson & Company Method for alleviation of extrapyramidal motor disorders
CA1337429C (en) 1983-12-05 1995-10-24 Guy Rosalia Eugene Van Lommen Derivatives of 2,2'-iminobisethanol
SE460947B (sv) * 1986-08-26 1989-12-11 Lejus Medical Ab En multiple-unit-dos komposition av l-dopa
DE3901814A1 (de) 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
DE69123090D1 (de) 1990-07-06 1996-12-19 Yoshitomi Pharmaceutical Kondensierte Thiophenverbindungen und deren Verwendung
DE4135474A1 (de) 1991-10-28 1993-04-29 Bayer Ag 2-aminomethyl-chromane
US5314888A (en) 1992-02-21 1994-05-24 Trustees Of Tufts College Veterinary method for treating inappropriate elimination of urine in household pets
SI9300097B (en) 1992-02-27 2001-12-31 Janssen Pharmaceutica Nv (benzodioxan, benzofuran or benzopyran) alkylamino) alkyl substituted guanidines
JPH07507058A (ja) 1992-03-11 1995-08-03 インターニューロン　ファーマシューティカルズ，インコーポレーテッド 大型の中性アミノ酸（ｌｎａａ）の血中濃度の食後変動の低減
DE4226527A1 (de) 1992-08-11 1994-02-17 Merck Patent Gmbh 1,4-Benzodioxanderivate
GB9302622D0 (en) 1993-02-10 1993-03-24 Wellcome Found Heteroaromatic compounds
ZA954688B (en) 1994-06-08 1996-01-29 Lundbeck & Co As H Serotonin 5-HT1A and dopamin D2 receptor ligands
PT707007E (pt) 1994-10-14 2002-06-28 Merck Patent Gmbh Derivados amino(tio)eter como agentes activos no snc
US5502080A (en) 1994-11-01 1996-03-26 Hitzig; Pietr Combined use of dopamine and serotonin agonists in the treatment of allergic disorders
US5554383A (en) 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
US5541199A (en) 1995-06-02 1996-07-30 American Home Products Corporation Chroman-2-ylmethylamino derivatives
GB9514380D0 (en) 1995-07-13 1995-09-13 Knoll Ag Therapeutic agents
JP4108747B2 (ja) 1995-07-13 2008-06-25 アボット ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 治療薬としてのピペラジン誘導体
US5670667A (en) 1995-07-25 1997-09-23 American Home Products Corporation Chroman-2-ylmethylamino derivatives
US5756521A (en) 1996-04-03 1998-05-26 American Home Products Corporation Chroman-2-ylmethylamino derivatives
DE19648384A1 (de) 1996-11-22 1998-05-28 Merck Patent Gmbh Fluorene, Dibenzofurane und Dibenzothiophene
EP0900792B1 (en) 1997-09-02 2003-10-29 Duphar International Research B.V Piperazine and piperidine derivatives as 5-HT1A and dopamine D2-receptor (ant)agonists
ATE253058T1 (de) 1997-09-02 2003-11-15 Duphar Int Res Piperidin- und piperazin derivate als 5-ht1- rezeptor-agonisten
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
WO1999045906A1 (en) 1998-03-09 1999-09-16 Trustees Of Tufts College Treatment of compulsive behaviours in man and animals
AR015036A1 (es) 1998-04-29 2001-04-11 American Home Prod Derivados de indolilo antisicoticos, composicion farmaceutica que los contiene y su uso para la manufactura de un medicamento
UA71590C2 (en) 1998-11-13 2004-12-15 Duphar Int Res Piperazine and piperidine derivatives
UA73981C2 (en) * 2000-03-10 2005-10-17 Merck Patent Gmbh (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit

Also Published As

Publication number Publication date
PL367291A1 (en) 2005-02-21
CA2455621C (en) 2010-11-16
WO2003009835A2 (en) 2003-02-06
US20040171645A1 (en) 2004-09-02
EP1408964A2 (en) 2004-04-21
DE60217870D1 (de) 2007-03-15
PT1408964E (pt) 2007-05-31
DK1408964T3 (da) 2007-05-21
MY134059A (en) 2007-11-30
RU2297833C2 (ru) 2007-04-27
CA2455621A1 (en) 2003-02-06
JP2004538289A (ja) 2004-12-24
MXPA04000775A (es) 2004-04-20
KR20040029325A (ko) 2004-04-06
SI1408964T1 (sl) 2007-06-30
AR037496A1 (es) 2004-11-17
ATE352302T1 (de) 2007-02-15
HK1068793A1 (en) 2005-07-29
BR0211358A (pt) 2004-09-21
DE60217870T2 (de) 2007-11-15
WO2003009835A3 (en) 2003-08-07
AU2002355170B2 (en) 2007-06-07
RU2004105844A (ru) 2005-05-10
CN1535150A (zh) 2004-10-06
US7872030B2 (en) 2011-01-18
ES2280602T3 (es) 2007-09-16
CN1292749C (zh) 2007-01-03
PL208258B1 (pl) 2011-04-29
PE20030277A1 (es) 2003-03-25
HUP0402092A2 (hu) 2005-02-28
EP1408964B1 (en) 2007-01-24
HUP0402092A3 (en) 2010-06-28

Similar Documents

Publication Publication Date Title
CY1107616T1 (el) Καινοτομος χρηση της 2-[5-(4-φθοροφαινυλο)-3-πυριδυλομεθυλαμινομεθυλο]-χρωμανης και των φυσιολογικα αποδεκτων αλατων της
GB0117645D0 (en) Therapeutic stratergies for prevention and treatment of alzheimers disease
BG106825A (en) Substituted oxazolidinones and their use in the field of blood coagulation
ATE544452T1 (de) Pharmazeutisch aktive isoindolin-derivate
DE60327089D1 (de) Systeme zum verschieben und/oder zurückhalten von gewebe in den oberen atemwegen
HUP0301380A2 (hu) Roszuvasztatin (ZD-4522) felhasználása heterozigóta örökletes hiperkoleszterolémia kezelésére alkalmas gyógyszerkészítmény előállítására
CY1107383T1 (el) Αναστολεις της φωσφολιπασης α2 του κυτοπλασμικου διαλυματος
CY1110130T1 (el) Παραγωγα μορφολινης για χρηση ως αγωνιστες ντοπαμινης στην θεραπευτικη αγωγη σεξουαλικης δυσλειτουργιας i.α.
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
CY1109013T1 (el) Νεα 4,4΄-διθειοδις-(3-αμινοβουτανιο-1-σουλφονικα) παραγωγα και συνθεσεις που τα περιεχουν
DK1736158T3 (da) Anvendel af 1- 4-(5-cyanoindol-3-yl)butyl -4-(2-carbamoylbenzofuran-5-yl)piperazin samt de fysiologiske acceptable salte deraf
ATE410148T1 (de) Pharmazeutische zubereitung zur oralen verwendung von heparin und seinen derivaten
CY1105142T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
DK0981347T3 (da) Anvendelsen af levobupivacain i ansigtkirurgi
CY1112878T1 (el) Νεο αλας βενζοϋλογονανιδινης
RS51316B (sr) Nova upotreba (r)-(-)-2-/5-(4-fluorofenil)-3- piridilmetilaminometil/-hromana i njegovih fiziološki prihvatljivih soli
HUP0402654A2 (hu) 2-[(2'-Halogén-3',5'-dialkoxi-fenil)-imino]-imidazolidin-származékok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
CY1106129T1 (el) Κιταλοπραμη για την αγωγη της υψηλης πιεσεως του αιματος
SE9602262D0 (sv) New use of derivatives of cystine
DE60226126D1 (de) Verwendung von gamma-gt inhibitoren zur behandlung von chronischen degenerativerkrankungen
DE50313136D1 (de) Verwendung von dopamin-rezeptor-agonisten zur behandlung von hautgeschwülsten, warzen und narben
CY1106694T1 (el) Σουλφοναμιδια και παραγωγα αυτων που ρυθμιζουν τη δραστικοτητα ενδοθηλινης
EE04951B1 (et) R-(+)-alfa-(2,3-dimetoksfenl)-1-[2-(4-fluorofenl)etl]-4-piperidiinmetanooli kasutamine uneh„irete raviks
SE0201374D0 (sv) Pharmaceutical combination
EA200600441A1 (ru) Сукцинатная и малонатная соли транс-4-((1r,3s)-6хлор-3-фенилиндан-1-ил)-1,2,2-триметилпиперазина и их применение в качестве лекарственного средства